Tags

Type your tag names separated by a space and hit enter

Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Int J Cancer 2020; 146(2):413-423IJ

Abstract

In the OS2006 study, patients younger than 18 years were treated with a methotrexate-based regimen (MTX), patients older than 25 years with a doxorubicin-cisplatin-ifosfamide-based regimen (API-AI), whereas patients aged 18-25 years received either API-AI or MTX. We herein report the prespecified subgroup analysis of the outcome of 106 patients treated with API-AI. Preoperative chemotherapy combined three doxorubicin-ifosfamide-cisplatin (API) and two doxorubicin-ifosfamide (AI) courses. Postoperative chemotherapy was assigned by risk group: localised patients with a good histological response (<10% viable cells) received two AI and two cisplatin-ifosfamide (PI) courses; patients with synchronous metastases, poor histological response or unresectable primary received five cycles of etoposide-ifosfamide (EI). Of the 106 patients, 61 were randomised to receive or not zoledronate. Median age was 30 years (range 18-67), 66 (62%) patients were >25 years. The primary tumours were axial in 28 patients (26%), and 28 (26%) presented with metastases. Ninety-six patients (91%) had surgery, conservative in 82 (85%); 36 patients (38%, 95% CI 28-48%) were good responders. Toxicity was manageable, with no significant difference in severe acute toxicity between patients aged >25 years and those younger. With a median follow-up of 4.8 years, the 5-year event-free survival and overall survival rates were 46% (95% CI 36-56) and 57% (95% CI 47-67), respectively. The primary tumour size and initial metastases correlated with a higher risk of event. In these 106 osteosarcoma adult patients, API-AI proved feasible with no excess of toxicity, and favourable activity despite poor-prognosis factors.

Authors+Show Affiliations

Department of Medical Oncology, Institut Curie, Paris, France.Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.Biostatistics Unit, Gustave Roussy, Villejuif, France.Department of Medical Oncology, Institut Curie, Paris, France.Department of Medicine, Val d'Aurelle Institute, Montpellier, France.Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.Department of Medical Oncology, Centre Oscar Lambret, CHRU, Lille, France.Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.Department of Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.Department of Medicine and Surgery, Gustave Roussy, Villejuif, France.Department of Medical Oncology, Institut Bergonié, Bordeaux, France.Orthopaedic Department, Cochin University hospital, Paris, France.Department of Anatomopathology, University Hospital, Tours, France.Medical Oncology Department, Institut de Cancérologie de la Loire Lucien Neuwirth, St Priest en Jarez, France.Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.Department of Medical Oncology, Timone University Hospital, Marseille, France.Biostatistics Unit, Gustave Roussy, Villejuif, France. Paris-Saclay University, Paris-Sud University, CESP, INSERM, Villejuif, France.UNICANCER, Paris, France.Department of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31246277

Citation

Piperno-Neumann, Sophie, et al. "Results of API-AI Based Regimen in Osteosarcoma Adult Patients Included in the French OS2006/Sarcome-09 Study." International Journal of Cancer, vol. 146, no. 2, 2020, pp. 413-423.
Piperno-Neumann S, Ray-Coquard I, Occean BV, et al. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. Int J Cancer. 2020;146(2):413-423.
Piperno-Neumann, S., Ray-Coquard, I., Occean, B. V., Laurence, V., Cupissol, D., Perrin, C., ... Blay, J. Y. (2020). Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. International Journal of Cancer, 146(2), pp. 413-423. doi:10.1002/ijc.32526.
Piperno-Neumann S, et al. Results of API-AI Based Regimen in Osteosarcoma Adult Patients Included in the French OS2006/Sarcome-09 Study. Int J Cancer. 2020 Jan 15;146(2):413-423. PubMed PMID: 31246277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. AU - Piperno-Neumann,Sophie, AU - Ray-Coquard,Isabelle, AU - Occean,Bob-Valéry, AU - Laurence,Valérie, AU - Cupissol,Didier, AU - Perrin,Christophe, AU - Penel,Nicolas, AU - Bompas,Emmanuelle, AU - Rios,Maria, AU - Le Cesne,Axel, AU - Italiano,Antoine, AU - Anract,Philippe, AU - de Pinieux,Gonzague, AU - Collard,Olivier, AU - Bertucci,François, AU - Duffaud,Florence, AU - Le Deley,Marie-Cécile, AU - Delaye,Jessy, AU - Brugieres,Laurence, AU - Blay,Jean-Yves, Y1 - 2019/07/19/ PY - 2018/12/27/received PY - 2019/05/28/accepted PY - 2019/6/28/pubmed PY - 2019/6/28/medline PY - 2019/6/28/entrez KW - adult patients KW - doxorubicin-cisplatin-ifosfamide regimen KW - osteosarcoma SP - 413 EP - 423 JF - International journal of cancer JO - Int. J. Cancer VL - 146 IS - 2 N2 - In the OS2006 study, patients younger than 18 years were treated with a methotrexate-based regimen (MTX), patients older than 25 years with a doxorubicin-cisplatin-ifosfamide-based regimen (API-AI), whereas patients aged 18-25 years received either API-AI or MTX. We herein report the prespecified subgroup analysis of the outcome of 106 patients treated with API-AI. Preoperative chemotherapy combined three doxorubicin-ifosfamide-cisplatin (API) and two doxorubicin-ifosfamide (AI) courses. Postoperative chemotherapy was assigned by risk group: localised patients with a good histological response (<10% viable cells) received two AI and two cisplatin-ifosfamide (PI) courses; patients with synchronous metastases, poor histological response or unresectable primary received five cycles of etoposide-ifosfamide (EI). Of the 106 patients, 61 were randomised to receive or not zoledronate. Median age was 30 years (range 18-67), 66 (62%) patients were >25 years. The primary tumours were axial in 28 patients (26%), and 28 (26%) presented with metastases. Ninety-six patients (91%) had surgery, conservative in 82 (85%); 36 patients (38%, 95% CI 28-48%) were good responders. Toxicity was manageable, with no significant difference in severe acute toxicity between patients aged >25 years and those younger. With a median follow-up of 4.8 years, the 5-year event-free survival and overall survival rates were 46% (95% CI 36-56) and 57% (95% CI 47-67), respectively. The primary tumour size and initial metastases correlated with a higher risk of event. In these 106 osteosarcoma adult patients, API-AI proved feasible with no excess of toxicity, and favourable activity despite poor-prognosis factors. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/31246277/Results_of_API_AI_based_regimen_in_osteosarcoma_adult_patients_included_in_the_French_OS2006/Sarcome_09_study_ L2 - https://doi.org/10.1002/ijc.32526 DB - PRIME DP - Unbound Medicine ER -